| 
| 
|  |  | Press Releases |  |  |  |  |  | 
|  |  | Friday, August 25, 2023 |  |  |  
| Hua Medicine Announces 2023 Interim Results |  | First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022.  more info >> |  |  |  | Monday, October 10, 2022 |  |  |  
| Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |  | Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |  |  |  | Tuesday, June 7, 2022 |  |  |  
| Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |  | Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions.  more info >> |  |  |  | Friday, May 13, 2022 |  |  |  
| Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |  | Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |  |  |  | Thursday, March 17, 2022 |  |  |  
| Hua Medicine Announces 2021 Annual Results |  | Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin.  more info >> |  |  |  | Sunday, September 26, 2021 |  |  |  
| Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |  | Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |  |  |  | Wednesday, September 15, 2021 |  |  |  
| Hua and Sinopharm Announced Supply Chain Strategic Cooperation |  | On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).  more info >> |  |  |  | Thursday, August 19, 2021 |  |  |  
| Hua Medicine Announces 2021 Interim Results |  | Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period").  more info >> |  |  |  | Friday, April 23, 2021 |  |  |  
| Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |  | Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA).  more info >> |  |  |  | Friday, March 19, 2021 |  |  |  
| Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |  | Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |  |  |  |  |  |  |  |  |  |  |  | 
	|  |  | 
 
|  |  
| Latest Press Releases |  |  |  | 
| 
| Hitachi High-Tech Announces the SU9600: Next-Generation Ultrahigh-Resolution Scanning Electron Microscope with High Throughput Oct 31, 2025 0:45 JST
 |   |  |  |  
| Sharp to Introduce AQUOS sense10 Smartphone Oct 31, 2025 0:27 JST
 |   |  |  |  
| Fujitsu to provide digital ticketing service for NTT DOCOMO's new d ticket platform Oct 31, 2025 0:07 JST
 |   |  |  |  
| EESystem Triumphs Again: Courts Deem Jason Shurka's Claims "Baseless" and "Futile" Oct 31, 2025 21:45 HKT/SGT
 |   |  |  |  
| Autumn Lighting Fair, Outdoor and Tech Light Expo, Eco Expo Asia draw some 62,000 buyers Oct 31, 2025 19:56 HKT/SGT
 |   |  |  |  
| Saudi Arabia Assumes Chairmanship of INTOSAI Oct 31, 2025 19:45 HKT/SGT
 |   |  |  |  
| T-RIZE Strategically Collaborates with Republic and Canton to Launch the First New Construction Real Estate Equity Tokenization Deal on Canton Network, phase one of a $200M plan Oct 31, 2025 15:50 HKT/SGT
 |   |  |  |  
| IPO Watch - High-Margin International Business Scales Up Rapidly: Unpacking Hithium Energy Storage's Global Expansion Ambition Behind its Push for a Hong Kong Listing   Oct 31, 2025 15:20 HKT/SGT
 |  |  |  |  
| CIMC Group Announces the First Three Quarter Results for 2025 Oct 31, 2025 14:16 HKT/SGT
 |   |  |  |  
| Hong Kong delegation concludes mission in Riyadh Oct 31, 2025 11:19 HKT/SGT
 |   |  |  |  
| The Executive Centre Unveils New Premium Flexible Workspace at One IFC, Central Hong Kong   Oct 31, 2025 09:19 HKT/SGT
 |   |  |  |  
| Doubleview Gold Corp Announces Non-Brokered Private Placement of Flow-Through Shares at $1.00 per share along with Non-Flow-Through Units Oct 31, 2025 09:09 HKT/SGT
 |   |  |  |  
| HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus Oct 31, 2025 9:30 JST
 |   |  |  |  
| TruMerit's Peter Preziosi Elected President of the Conference of NGOs in Consultative Relationship With the United Nations Oct 31, 2025 04:00 HKT/SGT
 |   |  |  |  
| MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO's "Development of Technologies for Building a Competitive Hydrogen Supply Chain" Project Oct 30, 2025 23:14 JST
 |   |  |  |  |  |  | More Press release >> |  |  |  |  |  
|  |  
|  |  |  |